Literature DB >> 29961644

Patterns of Dietary Supplement Use in Children with Down Syndrome.

Amy Feldman Lewanda1, Margo Faust Gallegos1, Marshall Summar1.   

Abstract

OBJECTIVE: To determine the frequency of dietary supplement use for children with Down syndrome, and to obtain additional descriptive data regarding the age of initial treatment, cost, perceived benefits, and disclosure of use to the pediatrician. STUDY
DESIGN: An anonymous questionnaire in English and Spanish was created for parents of children under age 18 years with Down syndrome. Surveys were completed in our clinic, or accessed on a number of Down syndrome-related websites.
RESULTS: A total of 1167 responses were completed and analyzed. Forty nine percent of responders currently/previously gave their child supplement(s). The average child received 3 supplements (ranging from 1-18). Although Nutrivene, curcumin, and green tea extract were most common, over 150 different products were reported. Supplementation began most often in infancy, generally between age 4 and 6 months. Average cost was $90.53/month. Overall, 87% of users noted improvement, mainly in speech, immunity, and attention; 17% reported side-effects, predominantly gastrointestinal disturbance. Lack of improvement and cost were the main reasons for discontinuation. Most parents learned of supplements through a parent group or friend. In almost 20%, the pediatrician was unaware of the supplement use.
CONCLUSIONS: Almost one-half of parents surveyed administer or have administered supplement(s) to their children with Down syndrome. Many of the supplements have concerning ingredient profiles and are given to children too young to articulate potential ill effects. Providers need to be aware of these products and question families about their use.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  alternative medicine; complementary medicine

Mesh:

Year:  2018        PMID: 29961644     DOI: 10.1016/j.jpeds.2018.05.022

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  3 in total

1.  Usage of and attitudes about green tea extract and Epigallocathechin-3-gallate (EGCG) as a therapy in individuals with Down syndrome.

Authors:  Rachel Long; Montana L Drawbaugh; Charlene M Davis; Charles R Goodlett; Jane R Williams; Randall J Roper
Journal:  Complement Ther Med       Date:  2019-07-02       Impact factor: 2.446

2.  Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.

Authors:  Raza Jamal; Jonathan LaCombe; Roshni Patel; Matthew Blackwell; Jared R Thomas; Kourtney Sloan; Joseph M Wallace; Randall J Roper
Journal:  PLoS One       Date:  2022-02-23       Impact factor: 3.752

3.  Epigallocatechin-3-Gallate Plus Omega-3 Restores the Mitochondrial Complex I and F0F1-ATP Synthase Activities in PBMCs of Young Children with Down Syndrome: A Pilot Study of Safety and Efficacy.

Authors:  Iris Scala; Daniela Valenti; Valentina Scotto D'Aniello; Maria Marino; Maria Pia Riccio; Carmela Bravaccio; Rosa Anna Vacca; Pietro Strisciuglio
Journal:  Antioxidants (Basel)       Date:  2021-03-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.